Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
ZIMLAB.NS
BuyPremium GrowerZIM Laboratories Limited · Healthcare · India · $73M · Avg Vol: $122K/d
67
StockRankGet insider-trade alerts
Q
52
V
26
M
84
P/E (TTM)
160.7x
ROE
2.0%
D/E
0.4x
Dividend %
—
COMPANY DESCRIPTION
ZIM Laboratories Limited engages in the development, manufacture, and supply of generic pharmaceutical and nutraceutical products in India and internationally.
FINANCIAL SUMMARY (INR)
| Year | 2023 | 2024 | 2025 | 2026 | CAGR | TTM |
|---|---|---|---|---|---|---|
| Revenue | 3.9B | 3.6B | 3.6B | 3.6B | -2.5% | 4.0B |
| EPS (INR) | 5.01 | 3.54 | 2.50 | 1.19 | -38.1% | 0.83 |
| Shares | 48.7M | 48.7M | 48.7M | 53.5M | +9.8% | 53.5M |
| Debt | 620.0M | 1.1B | 1.2B | 1.3B | 26.8% | 1.3B |
| Equity | 2.0B | 2.4B | 2.5B | 3.0B | 13.9% | — |
| Op CF | 381.7M | 162.8M | 411.5M | 495.3M | 9.1% | 495.3M |
| Inv CF | -362.0M | -730.1M | -399.3M | -563.5M | — | — |
| Fin CF | 5.5M | 595.3M | -91.0M | 281.9M | — | — |
Loading 1Y...
PRICE (1Y)+17.7%
SMA 50SMA 200
Close
$1.40
RSI (14)
64.8
52W High
$1.44
From 52W High
1.0%
SCORE BREAKDOWN
Quality
52
ROIC
5.3%56.3
ROE
2.0%48.3
GP/Assets
39.0%76.5
Op. Margin
-3.1%30.8
FCF/Assets
1.0%50.0
Piotroski
668.8
Int. Cover
1.4x40.1
D/E Ratio
0.43x32.3
Current Ratio
1.45x25.0
Value
26
P/E (TTM)
160.7x4.1
EV/EBITDA
34.7x18.2
P/FCF
134.7x12.1
P/B
2.4x55.0
P/S
1.8x71.7
Div Yield
—N/A
Momentum
84
52W High %
97%97.8
RS 6M
102%96.7
SMA 50/200
1.30x93.5
EPS Rev 4W
—N/A
EPS Rev 12W
—N/A
EPS Improve
—N/A
Q Growth
—N/A
FUNDAMENTALS
Market Cap
$73M
P/E (Forward)
—
Gross Margin
53.0%
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of ZIMLAB.NS are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| ZIMLAB.NS | ZIM Laboratories Limited(you) | $73M | 67 | Buy |
| WANBURY.NS | Wanbury Limited | $91M | 69 | Buy |
| KILITCH.NS | Kilitch Drugs (India) Limited | $69M | 58 | Hold |
| BAFNAPH.NS | Bafna Pharmaceuticals Limited | $77M | 55 | Hold |
| THEMISMED.NS | Themis Medicare Limited | $129M | 62 | Hold |
| AMANTA.NS | Amanta Healthcare Limited | $83M | 81 | Strong Buy |
| BAJAJHCARE.NS | Bajaj HealthCare Limited | $120M | 59 | Hold |
| VALIANTLAB.NS | Valiant Laboratories Limited | $65M | 83 | Strong Buy |
| AHCL.NS | Anlon Healthcare Limited | $88M | 90 | Strong Buy |
| BETA.NS | Beta Drugs Limited | $228M | 72 | Buy |
Peer medians: ROE 11.9% · P/E 42.5x · Gross margin 59.4%